Tags

Type your tag names separated by a space and hit enter

[Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
Rev Gastroenterol Mex. 2004 Oct-Dec; 69(4):251-60.RG

Abstract

Nonsteroidal anti-inflammatory drug (NSAID) use is associated with both upper and lower gastrointestinal tract complications in 1 to 2% of patients using these drugs for 6 to 12 months. Gastroduodenal ulcers are also present in 30 to 50% of patients using NSAID. Dyspepsia is another frequent side effect that may or may not be associated with mucosal lesions. Main risk factors for NSAID-associated gastrointestinal complications include age > 60 years, ulcer history, high dose of NSAID, and concomitant use of anticoagulants, aspirin, or corticosteroids. Patients with risk factors that need NSAIDs should receive gastroprotection with proton pump inhibitors or misoprostol. Another gastrointestinal safer option is use of COX-2 selective NSAIDs (coxibs). Increased cardiovascular risk observed with long-term use of rofecoxib should be compared with other COX-2 selective and non-selective NSAID. In patients at very high risk, co-prescription of coxib with proton pump inhibitors has been recommended. In patients at risk, all these strategies are cost-effective.

Authors+Show Affiliations

Sección de Gastroenterología, Servicio de Aparato Digestivo, Hospital Clinico Universitario, Universidad de Zaragoza, Zaragoza, España. alanas@unizar.es

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

15765979

Citation

Lanas, Angel. "[Prevention and Treatment of Non-steroidal Anti-inflammatory Drug Gastroenteropathy]." Revista De Gastroenterologia De Mexico, vol. 69, no. 4, 2004, pp. 251-60.
Lanas A. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. Rev Gastroenterol Mex. 2004;69(4):251-60.
Lanas, A. (2004). [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. Revista De Gastroenterologia De Mexico, 69(4), 251-60.
Lanas A. [Prevention and Treatment of Non-steroidal Anti-inflammatory Drug Gastroenteropathy]. Rev Gastroenterol Mex. 2004 Oct-Dec;69(4):251-60. PubMed PMID: 15765979.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. A1 - Lanas,Angel, PY - 2005/3/16/pubmed PY - 2005/3/25/medline PY - 2005/3/16/entrez SP - 251 EP - 60 JF - Revista de gastroenterologia de Mexico JO - Rev Gastroenterol Mex VL - 69 IS - 4 N2 - Nonsteroidal anti-inflammatory drug (NSAID) use is associated with both upper and lower gastrointestinal tract complications in 1 to 2% of patients using these drugs for 6 to 12 months. Gastroduodenal ulcers are also present in 30 to 50% of patients using NSAID. Dyspepsia is another frequent side effect that may or may not be associated with mucosal lesions. Main risk factors for NSAID-associated gastrointestinal complications include age > 60 years, ulcer history, high dose of NSAID, and concomitant use of anticoagulants, aspirin, or corticosteroids. Patients with risk factors that need NSAIDs should receive gastroprotection with proton pump inhibitors or misoprostol. Another gastrointestinal safer option is use of COX-2 selective NSAIDs (coxibs). Increased cardiovascular risk observed with long-term use of rofecoxib should be compared with other COX-2 selective and non-selective NSAID. In patients at very high risk, co-prescription of coxib with proton pump inhibitors has been recommended. In patients at risk, all these strategies are cost-effective. SN - 0375-0906 UR - https://www.unboundmedicine.com/medline/citation/15765979/[Prevention_and_treatment_of_non_steroidal_anti_inflammatory_drug_gastroenteropathy]_ L2 - https://medlineplus.gov/pepticulcer.html DB - PRIME DP - Unbound Medicine ER -